Investor Service Announcement no. 4/2009 To: NASDAQ OMX Copenhagen; Hørsholm, Denmark, May 25, 2009 LifeCycle Pharma A/S to Present at the UBS Global Specialty Pharmaceuticals Conference 2009 in London on June 2-3, 2009. LifeCycle Pharma A/S (OMX: LCP) today announced that its CEO, Mr. Jim New, is scheduled to present a company update at the UBS Global Specialty Pharmaceuticals Conference 2009 in London at 10:00 AM GMT (London) on June 3, 2009. The two-day conference for the pharmaceutical industry is being held June 2-3, 2009, at the Waldorf Hilton, Aldwych in London. For more information, please contact: Dr. Jim New President & Chief Executive Officer Phone: + 45 7033 3300 Email: JSN@lcpharma.com or Peter Schøtt Knudsen Head of Investor Relations Phone: + 45 2055 3817 Email: PSK@lcpharma.com About LifeCycle Pharma A/S (LCP) Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide®, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.
LifeCycle Pharma A/S to Present at the UBS Global Specialty Pharmaceuticals Conference 2009 in London on June 2-3, 2009.
| Source: Veloxis Pharmaceuticals A/S
Attachments
